Israel’s Ministry of Health has approved Brainsway to market and sell the deep transcranial magnetic stimulation (TMS) device to four medical centres to treat neurological and psychopathological disorders.

Brainsway TMS systems is a noninvasive device which treats major depression, bipolar disorder and negative symptoms and cognitive impairment in schizophrenic patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Brainsway CEO Uzi Sofer said: "We are now working to update indications with the Israeli Ministry of Health to bring them more in line with the approvals that we’ve already received in Europe."